News
Videos
Conferences
Events
Resources
Subscribe

|Articles|April 20, 2017

Risk Factors and More: A Roundup of This Week's #CureFact Snippets

Author(s)CURE staff

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Image of jane.

Have You Taken Time to Grieve? Facing Hearing Loss and Cancer

ByJane Biehl Ph.D.

November 12th 2025

Image of woman.

Dealing With Peripheral Neuropathy After Breast Cancer Treatment

ByCynthia Malaran

November 12th 2025

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

Detalimogene Shows 62% Response Rate in Bladder Cancer Trial

BySpencer Feldman

November 12th 2025

Tracy Milgram-Posner

Tracy Milgram-Posner Discusses BRCAStrong and Breast Cancer Support

ByTracy Milgram-Posner

November 12th 2025

Angela Patterson

Finally Learning to Put Myself First

ByAngela Patterson

November 11th 2025

Trending on CURE

Emerging Treatments and Hopeful Advances in Pancreatic Cancer

Signatera Guides Bladder Cancer Treatment After Surgery

Finally Learning to Put Myself First

FDA Designates MB-105 to Speed Review for Relapsed T-Cell Lymphoma

Detalimogene Shows 62% Response Rate in Bladder Cancer Trial

© 2025 MJH Life Sciences^®

All rights reserved.